A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial)
Abstract Introduction Cytisinicline (known as cytisine), a nicotinic acetylcholine receptor partial agonist, is a smoking cessation aid currently marketed in Central and Eastern Europe using a 1.5-mg/tablet 25-day downward titration schedule. No prior studies have evaluated other doses or administra...
Published in: | Nicotine & Tobacco Research |
---|---|
Main Authors: | , , , , |
Other Authors: | |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Oxford University Press (OUP)
2021
|
Subjects: | |
Online Access: | http://dx.doi.org/10.1093/ntr/ntab073 http://academic.oup.com/ntr/advance-article-pdf/doi/10.1093/ntr/ntab073/38498471/ntab073.pdf http://academic.oup.com/ntr/article-pdf/23/10/1656/40080187/ntab073.pdf |
id |
croxfordunivpr:10.1093/ntr/ntab073 |
---|---|
record_format |
openpolar |
spelling |
croxfordunivpr:10.1093/ntr/ntab073 2024-10-13T14:10:06+00:00 A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial) Nides, Mitchell Rigotti, Nancy A Benowitz, Neal Clarke, Anthony Jacobs, Cindy Achieve Life Sciences, Inc 2021 http://dx.doi.org/10.1093/ntr/ntab073 http://academic.oup.com/ntr/advance-article-pdf/doi/10.1093/ntr/ntab073/38498471/ntab073.pdf http://academic.oup.com/ntr/article-pdf/23/10/1656/40080187/ntab073.pdf en eng Oxford University Press (OUP) http://creativecommons.org/licenses/by/4.0/ Nicotine & Tobacco Research volume 23, issue 10, page 1656-1663 ISSN 1469-994X journal-article 2021 croxfordunivpr https://doi.org/10.1093/ntr/ntab073 2024-09-17T04:28:50Z Abstract Introduction Cytisinicline (known as cytisine), a nicotinic acetylcholine receptor partial agonist, is a smoking cessation aid currently marketed in Central and Eastern Europe using a 1.5-mg/tablet 25-day downward titration schedule. No prior studies have evaluated other doses or administration schedules. This study evaluated the effects of a higher dosage and simplified dosing schedule on drug efficacy and tolerability. Methods ORCA-1 was a double-blind, randomized, placebo-controlled clinical trial that provided cytisinicline or placebo tablets plus behavioral support for 25 days. Adult smokers (>10 cigarettes daily) committed to quitting smoking were randomized to compare 2 cytisinicline doses (1.5 mg and 3 mg) versus placebo, and 2 administration schedules [downward titration versus 3 times daily (TID)]. Primary outcome was a reduction in expected cigarettes smoked at end of treatment; secondary outcomes were biochemically confirmed 7-day abstinence at Week 4 and continuous abstinence from Weeks 5 to 8. Results Among 254 participants, those in cytisinicline arms (regardless of dose or schedule) had greater reductions in cigarettes smoked versus placebo, with differences observed in 3 cytisinicline arms statistically significant versus placebo. All cytisinicline arms had statistically significantly higher abstinence rates at Week 4 versus placebo. Both cytisinicline arms using TID schedules had statistically significantly higher continuous abstinence rates from Weeks 5 to 8 compared with placebo. Participants in the cytisinicline 3-mg TID arm had the highest abstinence rate. There were no safety concerns with either 1.5-mg or 3-mg cytisinicline. Conclusion Based on simpler dose scheduling, excellent tolerability, and best-continued abstinence rate, cytisinicline 3-mg TID was selected for future Phase 3 studies. Implications Although the 1.5-mg 25-day titration schedule has been marketed in Central and Eastern Europe for decades, this study explored using a higher dosage and a simplified dosing ... Article in Journal/Newspaper Orca Oxford University Press Nicotine & Tobacco Research |
institution |
Open Polar |
collection |
Oxford University Press |
op_collection_id |
croxfordunivpr |
language |
English |
description |
Abstract Introduction Cytisinicline (known as cytisine), a nicotinic acetylcholine receptor partial agonist, is a smoking cessation aid currently marketed in Central and Eastern Europe using a 1.5-mg/tablet 25-day downward titration schedule. No prior studies have evaluated other doses or administration schedules. This study evaluated the effects of a higher dosage and simplified dosing schedule on drug efficacy and tolerability. Methods ORCA-1 was a double-blind, randomized, placebo-controlled clinical trial that provided cytisinicline or placebo tablets plus behavioral support for 25 days. Adult smokers (>10 cigarettes daily) committed to quitting smoking were randomized to compare 2 cytisinicline doses (1.5 mg and 3 mg) versus placebo, and 2 administration schedules [downward titration versus 3 times daily (TID)]. Primary outcome was a reduction in expected cigarettes smoked at end of treatment; secondary outcomes were biochemically confirmed 7-day abstinence at Week 4 and continuous abstinence from Weeks 5 to 8. Results Among 254 participants, those in cytisinicline arms (regardless of dose or schedule) had greater reductions in cigarettes smoked versus placebo, with differences observed in 3 cytisinicline arms statistically significant versus placebo. All cytisinicline arms had statistically significantly higher abstinence rates at Week 4 versus placebo. Both cytisinicline arms using TID schedules had statistically significantly higher continuous abstinence rates from Weeks 5 to 8 compared with placebo. Participants in the cytisinicline 3-mg TID arm had the highest abstinence rate. There were no safety concerns with either 1.5-mg or 3-mg cytisinicline. Conclusion Based on simpler dose scheduling, excellent tolerability, and best-continued abstinence rate, cytisinicline 3-mg TID was selected for future Phase 3 studies. Implications Although the 1.5-mg 25-day titration schedule has been marketed in Central and Eastern Europe for decades, this study explored using a higher dosage and a simplified dosing ... |
author2 |
Achieve Life Sciences, Inc |
format |
Article in Journal/Newspaper |
author |
Nides, Mitchell Rigotti, Nancy A Benowitz, Neal Clarke, Anthony Jacobs, Cindy |
spellingShingle |
Nides, Mitchell Rigotti, Nancy A Benowitz, Neal Clarke, Anthony Jacobs, Cindy A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial) |
author_facet |
Nides, Mitchell Rigotti, Nancy A Benowitz, Neal Clarke, Anthony Jacobs, Cindy |
author_sort |
Nides, Mitchell |
title |
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial) |
title_short |
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial) |
title_full |
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial) |
title_fullStr |
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial) |
title_full_unstemmed |
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial) |
title_sort |
multicenter, double-blind, randomized, placebo-controlled phase 2b trial of cytisinicline in adult smokers (the orca-1 trial) |
publisher |
Oxford University Press (OUP) |
publishDate |
2021 |
url |
http://dx.doi.org/10.1093/ntr/ntab073 http://academic.oup.com/ntr/advance-article-pdf/doi/10.1093/ntr/ntab073/38498471/ntab073.pdf http://academic.oup.com/ntr/article-pdf/23/10/1656/40080187/ntab073.pdf |
genre |
Orca |
genre_facet |
Orca |
op_source |
Nicotine & Tobacco Research volume 23, issue 10, page 1656-1663 ISSN 1469-994X |
op_rights |
http://creativecommons.org/licenses/by/4.0/ |
op_doi |
https://doi.org/10.1093/ntr/ntab073 |
container_title |
Nicotine & Tobacco Research |
_version_ |
1812817253859590144 |